506 related articles for article (PubMed ID: 32729745)
1. Safety profile of
Puente Gómez I; Verheust C; Hanssens L; Dolhain J
Expert Rev Vaccines; 2020 Aug; 19(8):771-779. PubMed ID: 32729745
[TBL] [Abstract][Full Text] [Related]
2. Immunization of preterm infants with GSK's hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity.
Omeñaca F; Vázquez L; Garcia-Corbeira P; Mesaros N; Hanssens L; Dolhain J; Gómez IP; Liese J; Knuf M
Vaccine; 2018 Feb; 36(7):986-996. PubMed ID: 29336924
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.
Vesikari T; Rivera L; Korhonen T; Ahonen A; Cheuvart B; Hezareh M; Janssens W; Mesaros N
Hum Vaccin Immunother; 2017 Jul; 13(7):1505-1515. PubMed ID: 28340322
[TBL] [Abstract][Full Text] [Related]
4. Safety and reactogenicity of DTPa-HBV-IPV/Hib and DTPa-IPV/I-Hib vaccines in a post-marketing surveillance setting.
Lim FS; Phua KB; Lee BW; Quak SH; Teoh YL; Ramakrishnan G; Han HH; Van Der Meeren O; Jacquets JM; Bock HL
Southeast Asian J Trop Med Public Health; 2011 Jan; 42(1):138-47. PubMed ID: 21323176
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age.
Arístegui J; Dal-Ré R; Díez-Delgado J; Marés J; Casanovas JM; García-Corbeira P; De Frutos E; Van Esso D; Verdaguer J; De la Flor J; Moraga F; Boceta R; García-Martínez JA
Vaccine; 2003 Sep; 21(25-26):3593-600. PubMed ID: 12922087
[TBL] [Abstract][Full Text] [Related]
6. Integrated Safety Profile of a New Approved, Fully Liquid DTaP5-HB-IPV-Hib Vaccine.
Xu J; Stek JE; Ziani E; Liu GF; Lee AW
Pediatr Infect Dis J; 2019 Apr; 38(4):439-443. PubMed ID: 30882742
[TBL] [Abstract][Full Text] [Related]
7. DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa): A Review of its Use as Primary and Booster Vaccination.
Dhillon S
Drugs; 2010 May; 70(8):1021-58. PubMed ID: 20481658
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States.
Klein NP; Abu-Elyazeed R; Cheuvart B; Janssens W; Mesaros N
Hum Vaccin Immunother; 2019; 15(4):809-821. PubMed ID: 30444673
[TBL] [Abstract][Full Text] [Related]
9. Hexavalent vaccines: increasing options for policy-makers and providers. A review of the data supporting interchangeability (substitution with vaccines containing fewer antigens) and mixed schedules from the same manufacturer.
Dolhain J; Janssens W; Mesaros N; Hanssens L; Fierens F
Expert Rev Vaccines; 2018 Jun; 17(6):513-524. PubMed ID: 29920121
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and reactogenicity of two regimens of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio and Haemophilus influenzae type b vaccines administered to infants primed at birth with hepatitis B vaccine.
Cheng HK; Rajadurai VS; Amin Z; Sriram B; Yee MF; Han HH; Bock HL; Safary A
Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):685-92. PubMed ID: 15689088
[TBL] [Abstract][Full Text] [Related]
11. Safety and reactogenicity of a novel DTPa-HBV-IPV combined vaccine given along with commercial Hib vaccines in comparison with separate concomitant administration of DTPa, Hib, and OPV vaccines in infants.
Zepp F; Schuind A; Meyer C; Sänger R; Kaufhold A; Willems P
Pediatrics; 2002 Apr; 109(4):e58. PubMed ID: 11927731
[TBL] [Abstract][Full Text] [Related]
12. Spotlight on DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa).
Dhillon S
BioDrugs; 2010 Oct; 24(5):299-302. PubMed ID: 20795752
[TBL] [Abstract][Full Text] [Related]
13. Primary vaccination of infants against hepatitis B can be completed using a combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliomyelitis-Haemophilus influenzae type B vaccine.
Lim FS; Han HH; Jacquet JM; Bock HL
Ann Acad Med Singap; 2007 Oct; 36(10):801-6. PubMed ID: 17987229
[TBL] [Abstract][Full Text] [Related]
14. Infant vaccine co-administration: review of 18 years of experience with GSK's hexavalent vaccine co-administered with routine childhood vaccines.
Dolhain J; Janssens W; Dindore V; Mihalyi A
Expert Rev Vaccines; 2020 May; 19(5):419-443. PubMed ID: 32419537
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of 3-dose primary vaccination with combined DTPa-HBV-IPV/Hib in Indian infants.
Lalwani SK; Agarkhedkar S; Sundaram B; Mahantashetti NS; Malshe N; Agarkhedkar S; Van Der Meeren O; Mehta S; Karkada N; Han HH; Mesaros N
Hum Vaccin Immunother; 2017 Jan; 13(1):120-127. PubMed ID: 27629913
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine and DTPa-IPV-Hib when coadministered as a 3-dose primary vaccination schedule in The Netherlands: a randomized controlled trial.
van den Bergh MR; Spijkerman J; François N; Swinnen K; Borys D; Schuerman L; Veenhoven RH; Sanders EA
Pediatr Infect Dis J; 2011 Sep; 30(9):e170-8. PubMed ID: 21487327
[TBL] [Abstract][Full Text] [Related]
17. Control of vaccine preventable diseases in Australian infants: reviewing a decade of experience with DTPa-HBV-IPV/Hib vaccine.
Bayliss J; Nissen M; Prakash D; Richmond P; Oh KB; Nolan T
Hum Vaccin Immunother; 2021 Jan; 17(1):176-190. PubMed ID: 32573398
[TBL] [Abstract][Full Text] [Related]
18. A randomized, dose-ranging assessment of the immunogenicity and safety of a booster dose of a combined diphtheria-tetanus-whole cell pertussis-hepatitis B-inactivated poliovirus-Hemophilus influenzae type b (DTPw-HBV-IPV/Hib) vaccine vs. co-administration of DTPw-HBV/Hib and IPV vaccines in 12 to 24 months old Filipino toddlers.
Quiambao B; Van Der Meeren O; Kolhe D; Gatchalian S
Hum Vaccin Immunother; 2012 Mar; 8(3):347-54. PubMed ID: 22330958
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity, Safety and Reactogenicity of a Booster Dose of the 10-Valent Pneumococcal Nontypeable H. influenzae Protein D Conjugate Vaccine Coadministered With DTPa-IPV-Hib in Dutch Children: A Randomized Controlled Trial.
van den Bergh MR; Spijkerman J; François N; Swinnen K; Borys D; Schuerman L; Veenhoven RH; Sanders EA
Pediatr Infect Dis J; 2016 Jul; 35(7):e206-19. PubMed ID: 27097348
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib).
Martinón-Torres F; Boisnard F; Thomas S; Sadorge C; Borrow R;
Vaccine; 2017 Jun; 35(30):3764-3772. PubMed ID: 28583305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
